PDGFRB and gastrointestinal stromal tumor: Fortunately, since GIST has high frequency of KIT and PDGFR mutation (approximately 80% of GISTs harbor KIT mutation, 10% involve PDGFR mutations), KIT and PDGFR inhibition has been recognized as the primary therapeutic modality for unresectable or metastatic GIST [171].